Cover Image
市場調查報告書

便秘治療藥的開發平台分析

Constipation Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

出版商 P&S Market Research Pvt. Ltd 商品編碼 606432
出版日期 內容資訊 英文 101 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
便秘治療藥的開發平台分析 Constipation Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
出版日期: 2017年12月01日 內容資訊: 英文 101 Pages
簡介

本報告提供便秘治療藥的開發平台,彙整開發平台概要,推動市場要素及阻礙因素分析,各階段·分子類型·投藥途徑的開發平台趨勢,藥物簡介,競爭環境,主要企業簡介等調查。

第1章 調查背景

  • 調查目的
  • 定義
  • 調查範圍
    • 開發平台分析:不同階段
    • 開發平台分析:各分子類型
    • 開發平台分析:各給藥途徑
  • 主要的相關利益者

第2章 調查手法

  • 2次調查
  • 本調查

第3章 摘要整理

第4章 開發平台預測

  • 概要
    • 症狀
    • 病理
    • 診斷
    • 治療
    • 流行病學
  • 促進因素
  • 阻礙因素
  • 便秘治療藥的開發平台分析
    • 不同階段
    • 各分子類型
    • 各給藥途徑
    • 各企業

第5章 便秘治療藥的開發平台分析:不同階段

  • 登記完畢:藥物簡介
    • Elobixibat
  • 第三階段實驗:藥物簡介
    • AJG 555
    • 其他
  • 第二階段實驗:藥物簡介
    • BLI 801
    • 其他
  • 第一階段實驗:藥物簡介
    • NGM 282
    • 其他
  • 臨床試驗前:藥物簡介

第6章 臨床試驗分析

  • 便秘治療藥的開發平台分析 - 各地區
  • 便秘治療藥的開發平台分析 - 各檢測狀況

第7章 競爭情形

  • 主要企業的基準
  • SWOT分析

第8章 企業簡介

  • Nordic Life Science Pipeline Inc.
  • Enterin Inc.
  • 其他的企業

第9章 附錄

  • 簡稱
  • 相關調查
目錄

The study analyzed that the constipation therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Most of the drugs in pipeline for the treatment of constipation are in late stage of development. Constipation is a common functional gastrointestinal (GI) disorder that is most prevalent in the elderly and female population. According to the journal Clinical Interventions in Aging, published in 2015, the prevalence of the disease is around 20% in the world population, varying between 2% and 27% in different countries. The economic impact of chronic constipation is significant in the U.S., with around 100,000 constipation-related hospitalizations annually.

Insights on pipeline segments

Pharmaceutical companies are developing various drug candidates for the treatment of constipation in different stages of development including Filed, Phase III, Phase II, Phase I, and Pre-clinical. Albireo Pharma Inc. is in the process of developing a drug candidate, which is in the Filed stage of development, for treating constipation. There are small molecules as well as peptide type drug candidates in development for the treatment of constipation. A majority of the constipation therapeutics pipeline drugs are being developed as an oral dosage form.

Increasing prevalence of GI disorders boosting the growth of constipation pipeline

There has been considerable increase in the prevalence of GI disorders, such as non-alcoholic fatty liver disease, diabetes, pancreatitis, and acidity, in people. These problems have a huge impact on the digestion process, which, in turn, causes constipation. It has also been observed that synthetic foods too cause indigestion in people, which results in constipation. Thus, unhealthy dietary behavior too increases the chances of occurrence of constipation. Thus, increasing prevalence of GI disorders contributes as one of the key drivers for the development of drugs to treat constipation.

Technological advancements for the development of drug candidates to treat constipation

With advances in technology, many pharmaceutical companies are leveraging new and improved technologies for the development of drug candidates to treat constipation. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. They also allow development of specific targeted therapies with better drug delivery. For instance, Ardelyx Inc. has developed a unique platform that enables to discover targets in the GI tract, which control health and disease processes to optimize drug candidates and to understand their mechanisms of action.

Some of the players involved in the development of drug candidates for the treatment of constipation are Nordic Life Science Pipeline Inc., Enterin Inc., and Yuhan Corporation Ltd.

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
    • 1.3.1 Pipeline Analysis by Phase
    • 1.3.2 Pipeline Analysis by Molecule Type
    • 1.3.3 Pipeline Analysis by Route of Administration
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 By Industry Participant
    • 2.2.2 By Company Type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Overview
    • 4.1.1 Signs and Symptoms
    • 4.1.2 Pathophysiology
    • 4.1.3 Diagnosis
    • 4.1.4 Treatment
    • 4.1.5 Epidemiology
  • 4.2 Key Drivers
    • 4.8.1 Driver 1
    • 4.8.2 Driver 2
  • 4.3 Key Barrier
    • 4.9.1 Barrier 1
  • 4.4 Constipations Therapeutics Pipeline Analysis
    • 4.4.1 Pipeline Analysis by Phase
    • 4.4.2 Pipeline Analysis by Molecule Type
    • 4.4.3 Pipeline Analysis by Route of Administration
    • 4.4.4 Pipeline Analysis by Company

Chapter 5. Constipation Therapeutics Pipeline Analysis by Phase (2017)

  • 5.1 Filed
    • 5.1.1 Elobixibat
      • 5.1.1.1 Clinical trials
      • 5.1.1.2 Clinical results
      • 5.1.1.3 Strategic developments
  • 5.2 Phase III
    • 5.2.1 AJG 555
      • 5.2.1.1 Clinical trials
      • 5.2.1.2 Others
    • 5.2.2 XXXX
      • 5.2.2.1 Clinical trials
    • 5.2.3 XXXX
      • 5.2.3.1 Clinical trials
      • 5.2.3.2 Clinical results
      • 5.2.3.3 Others
      • 5.2.3.4 Technology
  • 5.3 Phase II
    • 5.3.1 BLI 801
      • 5.3.1.1 Clinical trials
    • 5.3.2 XXXX
      • 5.3.2.1 Clinical trials
    • 5.3.3 XXXX
      • 5.3.3.1 Clinical trials
    • 5.3.4 XXXX
      • 5.3.4.1 Strategic developments
    • 5.3.5 XXXX
      • 5.3.5.1 Clinical trials
      • 5.3.5.2 Strategic developments
    • 5.3.6 XXXX
      • 5.3.6.1 Clinical trials
    • 5.3.7 XXXX
      • 5.3.7.1 Clinical trials
      • 5.3.7.2 Clinical results
    • 5.3.8 XXXX
      • 5.3.8.1 Clinical trials
      • 5.3.8.2 Clinical results
    • 5.3.9 XXXX
      • 5.3.9.1 Clinical trials
      • 5.3.9.2 Technology
    • 5.3.10 XXXX
      • 5.3.10.1 Clinical trials
      • 5.3.10.2 Clinical results
      • 5.3.10.3 Strategic developments
  • 5.4 Phase I
    • 5.4.1 NGM 282
      • 5.4.1.1 Clinical trials
      • 5.4.1.2 Strategic developments
      • 5.4.1.3 Technology
    • 5.4.2 XXXX
      • 5.4.2.1 Clinical trials
  • 5.5 Pre-Clinical
    • 5.5.1 XXXX
      • 5.5.1.1 Others
      • 5.5.1.2 Technology
    • 5.5.2 XXXX

Chapter 6. Clinical Trials Analysis

  • 6.1 Clinical Trials by Region for Constipation Therapeutics Pipeline
  • 6.2 Clinical Trials by Trial Status for Constipation Therapeutics Pipeline

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for Constipation Therapeutics Pipeline
  • 7.2 SWOT Analysis of Constipation Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Nordic Life Science Pipeline Inc.
    • 8.1.1 Business Overview
    • 8.1.2 Pipeline Products
  • 8.2 Enterin Inc.
    • 8.2.1 Business Overview
    • 8.2.2 Pipeline Products
  • 8.3 XXXX
    • 8.3.1 Business Overview
    • 8.3.2 Pipeline Products
  • 8.4 XXXX
    • 8.4.1 Business Overview
    • 8.4.2 Pipeline Products
  • 8.5 XXXX
    • 8.5.1 Business Overview
    • 8.5.2 Pipeline Products
  • 8.6 XXXX
    • 8.6.1 Business Overview
    • 8.6.2 Pipeline Products
  • 8.7 XXXX
    • 8.7.1 Business Overview
    • 8.7.2 Pipeline Products
  • 8.8 XXXX
    • 8.8.1 Business Overview
    • 8.8.2 Pipeline Products
  • 8.9 XXXX
    • 8.9.1 Business Overview
    • 8.9.2 Pipeline Products

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS OF CONSTIPATION THERAPEUTICS, BY COMPANY (2017)
  • TABLE 2 DESCRIPTION OF ELOBIXIBAT
  • TABLE 3 CLINICAL TRIALS OF ELOBIXIBAT
  • TABLE 4 DESCRIPTION OF AJG 555
  • TABLE 5 CLINICAL TRIALS OF AJG 555
  • TABLE 6 DESCRIPTION OF XXXX
  • TABLE 7 CLINICAL TRIALS OF XXXX
  • TABLE 8 DESCRIPTION OF XXXX
  • TABLE 9 CLINICAL TRIALS OF XXXX
  • TABLE 10 DESCRIPTION OF BLI 801
  • TABLE 11 CLINICAL TRIALS OF BLI 801
  • TABLE 12 DESCRIPTION OF XXXX
  • TABLE 13 CLINICAL TRIALS OF XXXX
  • TABLE 14 DESCRIPTION OF XXXX
  • TABLE 15 CLINICAL TRIALS OF XXXX
  • TABLE 16 DESCRIPTION OF XXXX
  • TABLE 17 DESCRIPTION OF XXXX
  • TABLE 18 CLINICAL TRIALS OF XXXX
  • TABLE 19 DESCRIPTION OF XXXX
  • TABLE 20 CLINICAL TRIALS OF XXXX
  • TABLE 21 DESCRIPTION OF XXXX
  • TABLE 22 CLINICAL TRIALS OF XXXX
  • TABLE 23 DESCRIPTION OF XXXX
  • TABLE 24 CLINICAL TRIALS OF XXXX
  • TABLE 25 DESCRIPTION OF XXXX
  • TABLE 26 CLINICAL TRIALS OF XXXX
  • TABLE 27 DESCRIPTION OF XXXX
  • TABLE 28 CLINICAL TRIALS OF XXXX
  • TABLE 29 DESCRIPTION OF NGM 282
  • TABLE 30 CLINICAL TRIALS OF NGM 282
  • TABLE 31 DESCRIPTION OF XXXX
  • TABLE 32 CLINICAL TRIALS OF XXXX
  • TABLE 33 DESCRIPTION OF XXXX
  • TABLE 34 DESCRIPTION OF XXXX
  • TABLE 35 NORDIC LIFE SCIENCE PIPELINE INC. - AT A GLANCE
  • TABLE 36 ENTERIN INC. - AT A GLANCE
  • TABLE 37 XXXX - AT A GLANCE
  • TABLE 38 XXXX - AT A GLANCE
  • TABLE 39 XXXX - AT A GLANCE
  • TABLE 40 XXXX - AT A GLANCE
  • TABLE 41 XXXX - AT A GLANCE
  • TABLE 42 XXXX - AT A GLANCE
  • TABLE 43 XXXX - AT A GLANCE

LIST OF FIGURES

  • FIG 1 RESEARCH METHODOLOGY
  • FIG 2 SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 5 CONSTIPATION DRUG CANDIDATES UNDER DEVELOPMENT (2017)
  • FIG 6 CONSTIPATION THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
  • FIG 7 CONSTIPATION THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
  • FIG 8 CLINICAL RESULTS CHART OF XXXX
  • FIG 9 CLINICAL RESULT OF XXXX
  • FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • FIG 11 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • FIG 12 KEY PLAYERS BENCHMARKING
  • FIG 13 SWOT ANALYSIS
Back to Top